Marimastat in Recurrent Colorectal Cancer
Author Information
Author(s): Primrose J N, Bleiberg H, Daniel F, Belle S Van, Mansi J L, Seymour M, Johnson P W, Neoptolemos J P, Baillet M, Barker K, Berrington A, Brown P D, Millar A W, Lynch K P
Primary Institution: University Surgery Unit, Southampton General Hospital
Hypothesis
Does marimastat have biological activity in patients with recurrent colorectal cancer as measured by carcinoembryonic antigen levels?
Conclusion
Marimastat was associated with dose-dependent biological effects in cancer patients.
Supporting Evidence
- The proportion of patients with biological effects was higher with twice daily dosing compared to once daily dosing.
- Median rates of rise of CEA fell significantly during treatment for patients receiving twice daily marimastat.
Takeaway
This study tested a drug called marimastat on cancer patients to see if it could help lower a specific cancer marker in their blood.
Methodology
A pilot, escalating-dose study of oral marimastat was performed with patients receiving different doses for 28 days while monitoring CEA levels.
Potential Biases
Potential bias in patient selection and reporting of adverse events.
Limitations
The study primarily focused on short-term biological effects and did not assess long-term efficacy or tolerability.
Participant Demographics
Patients with recurrent colorectal cancer and elevated serum CEA levels.
Statistical Information
P-Value
0.043
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website